

Differential involvement of ERK₁₋₂ and p38^{MAPK} activation on Swiss 3T3 cell proliferation induced by prostaglandin F_{2α}

Andrés Dekanty^a, Sebastián Giulianelli^a, Omar A. Coso^b, Philip S. Rudland^c,
Luis Jimenez de Asua^{a,c,*}

^a *Fundación Instituto Leloir, Av. Patricias Argentinas 435, 1405 Buenos Aires, Argentina*

^b *Laboratorio de Fisiología y Biología Molecular, FCEyN, Universidad de Buenos Aires, 1428 Buenos Aires, Argentina*

^c *School of Biological Sciences, University of Liverpool, Liverpool L69 3BX, United Kingdom*

Received 9 January 2006; revised 20 March 2006; accepted 27 March 2006

Available online 7 April 2006

Edited by Veli-Pekka Lehto

Abstract Prostaglandin F_{2α} (PGF_{2α}) induces cyclin D₁ expression and DNA synthesis in Swiss 3T3 cells. In order to assess which signaling mechanisms are implicated in these processes, we have used both a pharmacological approach and interfering mutants. We demonstrate that PGF_{2α} induces extracellular-signal-regulated kinase (ERK₁₋₂) and p38^{MAPK} activation, and inhibition of any of these signaling pathways completely blocks PGF_{2α}-stimulated DNA synthesis. We also show that ERK₁₋₂, but not p38^{MAPK} activation is required to induce cyclin D₁ expression, strongly suggesting that the concerted action of cyclin D₁ gene expression and other events are required to induce complete phosphorylation of retinoblastoma protein and S-phase entry in response to PGF_{2α}.

© 2006 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

Keywords: Prostaglandin F_{2α}; MAPK; ERK₁₋₂; p38^{MAPK}; Cyclin D₁; S-phase

1. Introduction

Mammalian cells proliferation is a highly coordinated phenomenon generally regulated by growth factors and extracellular matrix adhesion [1–4]. Most growth factors bind and activate receptors of tyrosine kinase, triggering the activation of specific signal transduction pathways. These mitogen-induced signals concertedly modulate the initiation of DNA replication and cell division, and this occurs by triggering a cascade of events that ultimately induce the expression of G₁ cyclins, key molecules that regulate crucial cell cycle transitions [5–7]. Several lines of evidence support the idea that cyclin Ds exert the main control on the transition of G₀ to S phase [6,8], and that most growth factors control G₁ phase progression by triggering the expression of cyclin Ds [9,10].

Prostaglandin F_{2α} (PGF_{2α}) stimulates DNA synthesis and proliferation of cultured Swiss mouse 3T3 cells [11], and is implicated in unrestricted multiplication of transformed cells [12]. Our previous work reveals that several PGF_{2α}-triggered signaling events are required to induce cellular entry into S-phase, including increases in diacylglycerol, inositol 1,4,5-trisphosphate, intracellular Ca²⁺ ion mobilization, and protein kinase C (PKC) activation [11,13]. We have also shown that PGF_{2α} induction of cyclin D₁ expression plays a pivotal role in the control of DNA replication and the PGF_{2α}-triggered cyclin D₁ expression involves a PKC-independent event, since PGF_{2α} is able to increase cyclin D₁ mRNA/protein levels in PKC-depleted cells [14]. Such a PKC-independent process may correspond to other early PGF_{2α}-triggered events and both PKC-dependent and independent signals appear to be concertedly required for cells to initiate DNA synthesis. Furthermore, PGF_{2α} appears to induce DNA synthesis via the combined actions of the induction of cyclin D₁ gene expression and other signaling pathway-triggered events [14]. Thus, a basic question regarding PGF_{2α} signaling mechanisms is whether, and how, each personalized PGF_{2α} signal regulates cyclin D₁ expression, and how such events and others can ultimately control initiation of DNA synthesis.

Here we report that PGF_{2α} causes extracellular-signal-regulated kinase (ERK₁₋₂) and p38^{MAPK} activation in Swiss 3T3 cells. Using a pharmacological approach as well as stable transfected cells with a dominant negative mutant of p38^{MAPK} we determined that ERK₁₋₂ and p38^{MAPK} activation are essential for PGF_{2α}-stimulated cellular entry into S-phase. We also show that ERK₁₋₂ but not p38^{MAPK} activation, is an essential event required to induce cyclin D₁ expression, suggesting that p38^{MAPK} activation is involved in eliciting another process different from cyclin D₁ gene expression required to induce DNA synthesis in response to PGF_{2α}.

2. Materials and methods

2.1. Cell culture

Swiss mouse 3T3 cells [15] were grown in DMEM containing 10% (v/v) fetal calf serum. Sub-confluent cultures were grown in 100-mm dishes at 37 °C equilibrated with 10% (v/v) CO₂.

2.2. Initiation of DNA synthesis assay

DNA synthesis analysis was performed as previously described [4]. Briefly, 1.5 × 10⁵ cells were seeded in 35 mm dishes and growth until confluent and quiescent (6–8 days). Then cells were stimulated by addition of

* Corresponding author. Fax: +5411 52387501.

E-mail address: ljimenez@leloir.org.ar (L. Jimenez de Asua).

Abbreviations: PGF_{2α}, Prostaglandin F_{2α}; ERK, extracellular-signal-regulated kinase; MAPK, mitogen activated protein kinase; pRb, retinoblastoma protein; FBS, fetal bovine serum; LIF, leukaemia inhibitory factor; Me₂SO, dimethyl sulfoxide

growth factors and labeled with [methyl ^3H] thymidine for 28 h and processed for autoradiography. The percentage of cells that initiated DNA synthesis at a given time was determined as previously described [4,16].

2.3. Transfection

For stable transfections, 10^6 cells/ml were electroporated with pcDNA3.1 vector encoding *flag*-tagged wild type or dominant-negative-p38^{MAPK} [17]. After selection with G418 (400 $\mu\text{g}/\text{ml}$) and limiting dilution, multiple resistant clones were isolated and tested for p38^{MAPK} expression using anti-*flag* antibody. Cloned cells expressing the transgene were analyzed for cell proliferation and protein expression. The p38^{MAPK} constructs were a kind gift of Dr. JiaHuai Han, Scripps Research Institute, La Jolla, CA.

2.4. SDS-PAGE and immunoblotting

Protein extracts were prepared as in Sauane et al. [14]. Fifty micrograms of protein were separated on SDS-polyacrylamide gels and blotted onto nitrocellulose membranes. Thereafter, membranes were blocked and incubated overnight in the primary antibody diluted in 5% (w/v) non-fat milk in TBS-T. The primary antibodies used were: phospho-ERK₁₋₂ (#sc-7383), ERK₂ (#sc-154), p38^{MAPK} (#sc-535), cdk4 (#sc-260), cyclin D₁ (#sc-450) from Santa Cruz Biotechnology; phospho-p38^{MAPK} (#9211) from Cell Signaling; Retinoblastoma (pRb) (#14001A) from Pharmingen; *flag* (#F3165) from Sigma. Membranes were washed with TBS-T and incubated with peroxidase-conjugated secondary antibodies (Dako). The immunoblots were developed with the ECL detection reagent (Amersham). All the data shown are representative of three independent experiments.

2.5. Cyclin-dependent kinase assay

Cyclin D/cdk4-associated kinase activity was performed as described previously [18]. Briefly, quiescent and confluent cells were stimulated and harvested at the indicated times. Cyclin/cdk4 complex was immunoprecipitated with an anti-cdk4 antibody. Kinase activity was measured using 0.5 μg GST-pRb as the substrate and 10 μCi [γ - ^{32}P]ATP at 30 °C for 30 min. Reaction was stopped and analyzed by SDS-PAGE and autoradiography.

3. Results and discussion

ERK₁₋₂ and p38^{MAPK} signaling pathways are involved in a diverse array of cellular responses. While MEK/ERK₁₋₂ is a well-characterized signaling pathway activated by growth factors and involved in cell proliferation, there is less evidence linking p38^{MAPK} activation with cell proliferation. In order to gain insights about the early signaling mechanisms that mediate the PGF_{2 α} mitogenic response in Swiss 3T3 cells, we performed a Western blot analysis using specific antibodies for the activated form of ERK₁₋₂ (phospho-Thr²⁰⁰/Tyr²⁰⁴). PGF_{2 α} promoted a sustained ERK₁₋₂ activation, inducing a maximum increase at 5 min (Fig. 1A), remaining active for at least 8 h (data not shown). The same results were obtained when ERK₁₋₂ activation was determined by an immunoprecipitation in vitro kinase activity assay (data not shown). Treatment of Swiss 3T3 cells with U0126, a specific inhibitor of MEK₁ and thus ERK₁₋₂ activation [19], caused a concentration-dependent reduction in PGF_{2 α} -induced ERK₁₋₂ activation (Fig. 1B). In order to assess whether ERK₁₋₂ activation is required for the mitogenic effect of PGF_{2 α} , we treated the cells with U0126 before stimulation and DNA synthesis was measured. Interestingly, U0126 treatment strongly suppressed PGF_{2 α} -induction of DNA synthesis in a dose-dependent manner (Fig. 1C), whilst U0126 treatment did not significantly affect the mitogenic stimulus of fetal bovine serum (FBS) (Fig. 1C). This result suggested that the MEK₁/ERK₁₋₂ signaling pathway is critically involved in the PGF_{2 α} -proliferative response.

PGF_{2 α} -stimulation of DNA synthesis in Swiss 3T3 cells also requires PKC activation [14], and PKC activation has been shown to be one of the possible pathways leading to ERK₁₋₂




Fig. 1. U0126 blocked PGF_{2 α} -triggered ERK₁₋₂ activation and DNA synthesis. Quiescent cells were treated with PGF_{2 α} (300 ng/ml) in the absence (A) or presence of U0126 or solvent control dimethyl sulfoxide (Me₂SO) (B) or GF109203 (D) at the indicated times. Equal amounts of proteins were analyzed by Western blot using phospho-ERK₁₋₂ (upper panel) or ERK₂ antibodies (lower panel). (C) To measure the effect of ERK₁₋₂ inhibition on PGF_{2 α} -stimulated DNA synthesis, quiescent cells were untreated (□), treated with PGF_{2 α} (300 ng/ml; ◆) or FBS (10%; △) in the absence or presence of U0126 (0–15 μM). The percentage of S-phase cells was determined as described in Section 2. Results from one out of at least three independent experiments leading to the same conclusions are displayed.

activation [20]. Thus, to determine whether $\text{PGF}_{2\alpha}$ -triggered ERK_{1-2} activation is a downstream event of PKC activation, we used a specific PKC inhibitor (GF109203X). Interestingly, $\text{PGF}_{2\alpha}$ was still able to promote ERK_{1-2} activation in cells pre-treated with GF109203X (Fig. 1D), strongly suggesting that ERK_{1-2} activation is one of the early PKC-independent signals triggered by $\text{PGF}_{2\alpha}$ that are involved in the initiation of DNA synthesis.

To gather additional insights on $\text{PGF}_{2\alpha}$ -triggered signals, we carried out a Western blot analysis using an antibody specific for the activated form of p38^{MAPK} (phospho-Thr¹⁸⁰/Tyr¹⁸²). $\text{PGF}_{2\alpha}$ caused an increase in phospho- p38^{MAPK} levels after 5 min of $\text{PGF}_{2\alpha}$ addition (Fig. 2A) reaching levels comparable to those obtained with osmotic stress induced by NaCl addition (Fig. 2A). To determine the role of this activation in the $\text{PGF}_{2\alpha}$ proliferative response, we treated the cells with the pyridinyl imidazole SB203580, a specific inhibitor of p38^{MAPK} . The ability of $\text{PGF}_{2\alpha}$ to induce DNA synthesis in Swiss 3T3 cells was blocked by addition of SB203580, causing maximal inhibition at 10 μM (Fig. 2B), whilst SB203580 treatment did not significantly affect the mitogenic stimulus of FBS or leukaemia inhibitory factor (LIF) (Fig. 2B). Further confirmation that p38^{MAPK} is critically involved in $\text{PGF}_{2\alpha}$ -induction of DNA synthesis, we generated stable cell lines expressing wild type or dominant negative p38^{MAPK} (AF- p38^{MAPK}). Expression of phosphorylation-defective p38^{MAPK} mutant with substitutions at Thr¹⁸⁰ and Tyr¹⁸² by alanine and phenylalanine, respectively, has been shown to block p38^{MAPK} activation in vivo [21]. As shown in Fig. 2C, the percentage of cells entering into the S-phase in response to $\text{PGF}_{2\alpha}$ were comparable between empty vector and wild type- p38^{MAPK} transfected cells. In contrast, in AF- p38^{MAPK} transfected cells, $\text{PGF}_{2\alpha}$ failed to induce DNA synthesis (Fig. 2C). Cellular response to other mitogenic stimuli such as FBS or LIF was unaffected (Fig. 2C), consistent with a specific requirement of p38^{MAPK} activation in $\text{PGF}_{2\alpha}$ -induction of DNA synthesis.

We have previously reported that $\text{PGF}_{2\alpha}$ raised cyclin D₁ protein levels at 6–9 h, reaching a plateau value after 12–15 h and these levels remained relatively high for up to 21 h [14]. There is evidence that ERK_{1-2} activation raises cyclin D₁ levels, whilst p38^{MAPK} activation causes the downregulation of cyclin D₁ [22]. However, our results shown that both pathways are required for the $\text{PGF}_{2\alpha}$ induction of DNA synthesis. Thus, G₁-cyclins expression was determined in $\text{PGF}_{2\alpha}$ stimulated cells in the presence of MEK₁ and p38^{MAPK} inhibitors. Treatment of cells with U0126 caused a concentration-dependent reduction in $\text{PGF}_{2\alpha}$ -triggered increases of cyclin D₁ levels (Fig. 3A). In contrast, cyclin D₁ levels were not significantly affected in cells treated with SB203580 (Fig. 3A). As we have previously shown, cdk4 protein levels are constitutive and are not affected by any of these treatments (Fig. 3A). Consistent with the results obtained with SB203580, $\text{PGF}_{2\alpha}$ -triggered increases of cyclin D₁ expression were not affected in cells stable expressing flag-tagged wild type or AF- p38^{MAPK} proteins (Fig. 3B), further demonstrating that p38^{MAPK} activation is not involved in cyclin D₁ expression. We also evaluated the effect of MAPK inhibitors on cyclin D/cdk4 associated kinase activity. While U0126 caused a reduction in cyclin D/cdk4 kinase activity after $\text{PGF}_{2\alpha}$ stimulation (Fig. 3C), it was not significantly affected in SB203580-treated cells (Fig. 3C). These results show that the inhibitory effect of SB203580 on S-phase




Fig. 2. p38^{MAPK} activation is required for $\text{PGF}_{2\alpha}$ -triggered DNA synthesis. (A) Cells were treated with $\text{PGF}_{2\alpha}$ (300 ng/ml) for 5–60 min or treated with NaCl (500 mM) for 30 min. Equal amounts of protein were analyzed by Western blot using phospho- p38^{MAPK} (upper panel) or p38^{MAPK} antibodies (lower panel). Band intensity was quantified; numbers indicate the ratio of phospho- p38^{MAPK} / p38^{MAPK} expressed as fold induction respect to untreated cells. Results from one out of at least three independent experiments leading to the same conclusions are displayed. (B) To determine the effect of p38^{MAPK} inhibition on $\text{PGF}_{2\alpha}$ -stimulated DNA synthesis, quiescent cells were untreated (□), treated with $\text{PGF}_{2\alpha}$ (300 ng/ml; ◆), FBS (10%; ◊) or LIF (100 ng/ml; ×) in the absence or presence of SB203580 (0–15 μM). The percentage of S-phase cells was determined as described in Section 2. (C) Quiescent cultures of stable transfected cells [empty vector (black), p38^{MAPK} (grey) or AF- p38^{MAPK} (white)] were untreated (control), treated with $\text{PGF}_{2\alpha}$ (300 ng/ml), FBS (10%) or LIF (100 ng/ml). The percentage of S-phase cells was determined as described in Section 2. The experiments were undertaken with five independent clones of stable transfected cells with the same results.

entry is neither due to a regulation of cyclin D₁ protein levels nor by regulating the formation and activation of cyclin D/cdk4 kinase complex.

One event that precedes S-phase entry is hyper-phosphorylation of the pRb. To determine whether ERK_{1-2} and p38^{MAPK} pathways converge prior to pRb phosphorylation, we analyzed the phosphorylation state of pRb by Western blot after $\text{PGF}_{2\alpha}$ stimulation of Swiss 3T3 cells. After $\text{PGF}_{2\alpha}$ or FBS addition, pRb appeared as a more slowly migrating band corresponding to hyperphospho-pRb protein (Fig. 4A). In contrast, this shift in pRb migration was absent when cells were treated with $\text{PGF}_{2\alpha}$ together with either U0126 or SB203580 (Fig. 4A),




Fig. 3. PGF_{2 α} -triggered cyclin D1 expression and cyclin D/cdk4 activation require ERK₁₋₂ but not p38^{MAPK} activation. (A) Cells were untreated (c) or treated with PGF_{2 α} in the absence or presence of U0126 or SB203580. Cell extracts were prepared and equal amounts of protein analyzed by Western blot using cyclin D₁ (upper panel) or cdk4 antibodies (lower panel). (B) *flag*-tagged wild type or AF-p38^{MAPK} stable transfected cells were untreated or treated with PGF_{2 α} . Equal amounts of protein were analyzed by Western blot using cyclin D₁ (upper panel), *flag* (middle panel) or p38^{MAPK} antibodies (lower panel). All these experiments were undertaken with five independent clones of stable transfected cells with the same results. (C) Cyclin D/cdk4-associated kinase activity was measured in vitro after PGF_{2 α} -stimulation of cells for 20 h in the absence or presence of U0126, SB203580 (10 μ M) or equivalent amount of solvent (Me₂SO). Cyclin D/cdk4 complexes were immunoprecipitated and kinase activity measured using pRb-GST as substrate. Kinase reactions were analyzed by SDS-PAGE and autoradiography. Results from one out of at least three independent experiments leading to the same conclusions are displayed.

strongly suggesting that those events triggered by both signaling pathways are upstream of pRb. Similar results were obtained when cyclin A expression was analyzed (Fig. 4B);




Fig. 4. Involvement of ERK₁₋₂ and p38^{MAPK} on pRb phosphorylation and cyclin A expression. Cells were untreated (c), treated with FBS (10%) or treated with PGF_{2 α} (300 ng/ml) for 25 h in the presence of U0126 and SB203580 (10 μ M). Equal amounts of protein analyzed by Western blot using (A) a specific pRb antibody or (B) a specific cyclin A antibody. p-pRb; phosphorylated-pRb. Results from one out of at least three independent experiments leading to the same conclusions are displayed.

cyclin A is a transcriptional target of E2F and therefore downstream of pRb. These results further confirmed that both signaling pathways converge at a point prior to pRb. The results obtained using U0126 are as anticipated, since the inhibition of ERK₁₋₂ activation blocked cyclin D₁ expression and cyclin D/cdk4 activation. However, the results obtained with SB203580 suggest a role for p38^{MAPK} activation in another process, different from activation of the cyclin D/cdk4 complex that is upstream of pRb inhibition.

In summary, we have shown using a combination of biochemical approaches and interfering mutants that both ERK₁₋₂ and p38^{MAPK} activation are essential for PGF_{2 α} -stimulated S-phase entry. PGF_{2 α} promoted ERK₁₋₂ activation by a PKC-independent pathway, suggesting that ERK₁₋₂ is one of the early PKC-independent signaling events involved in PGF_{2 α} -triggered DNA synthesis. We have also shown that both signaling pathways converge at a point prior to pRb phosphorylation. ERK₁₋₂ activation is required to induce cyclin D₁ expression, consistent with previous studies linking sustained ERK activation with cyclin D₁ expression and cellular proliferation [23]. The finding that PGF_{2 α} triggers ERK₁₋₂ activation via a PKC-independent event are also supported by these results, since PKC inhibition blocked PGF_{2 α} 's mitogenic response, without affecting cyclin D₁ mRNA/protein expression [14]. p38^{MAPK} activation is not related to cyclin D₁




Fig. 5. Summary of PGF_{2 α} triggered signals: PGF_{2 α} induces PKC, ERK₁₋₂ and p38MAPK activation. Inhibition of any of these signaling pathways completely blocks PGF_{2 α} induction of DNA synthesis. ERK₁₋₂ activation is required to induce cyclin D1 expression, while p38MAPK activation is involved in eliciting another process, strongly suggesting that the concerted action of cyclin D1 gene expression and other events are required to induce complete phosphorylation of pRb and S-phase entry in response to PGF_{2 α} .

expression nor cyclin D/cdk4 kinase activation suggesting a role for p38^{MAPK} in another process, different from cyclin D/cdk4 activation, that is required to induce DNA synthesis (Fig. 5). The involvement of other cyclin/cdk complexes (e.g. cyclin E/cdk2) is the subject of current active investigation.

Acknowledgements: This study was supported by grants from the Association for International Cancer Research, No. 099–018, Scotland, UK, and The Cancer and Polio Research Fund (Liverpool) awarded to L.J.A. and P.S.R., respectively. A.D. was a Fellow of ANPCyT and O.A.C. and L.J.A. are investigators of the National Research Council (CONICET) of Argentina.

References

- [1] Tapon, N. and Hall, A. (1997) Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. *Curr. Opin. Cell Biol.* 9, 86–92.
- [2] Assoian, R.K. and Zhu, X. (1997) Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. *Curr. Opin. Cell Biol.* 9, 93–98.
- [3] Keely, P.J., Westwick, J.K., Whitehead, I.P., Der, C.J. and Parise, L.V. (1997) Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. *Nature* 390, 632–636.
- [4] Jimenez de Asua, L., Richmond, K.M. and Otto, A.M. (1981) Two growth factors and two hormones regulate initiation of DNA synthesis in cultured mouse cells through different pathways of events. *Proc. Natl. Acad. Sci. USA* 78, 1004–1008.
- [5] Peter, M. and Herskowitz, I. (1994) Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. *Cell* 79, 181–184.
- [6] Hunter, T. and Pines, J. (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. *Cell* 79, 573–582.
- [7] Berridge, M.J. (1993) Cell signalling. A tale of two messengers. *Nature* 365, 388–389.
- [8] Matsushime, H., Roussel, M.F., Ashmun, R.A. and Sherr, C.J. (1991) Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. *Cell* 65, 701–713.
- [9] Sherr, C.J. and Roberts, J.M. (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev.* 9, 1149–1163.
- [10] Rivard, N., L'Allemain, G., Bartek, J. and Pouyssegur, J. (1996) Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. *J. Biol. Chem.* 271, 18337–18341.
- [11] Goin, M., Pignataro, O. and Jimenez de Asua, L. (1993) Early cell cycle diacylglycerol (DAG) content and protein kinase C (PKC) activity enhancement potentiates prostaglandin F2 alpha (PGF2 alpha) induced mitogenesis in Swiss 3T3 cells. *FEBS Lett.* 316, 68–72.
- [12] Sales, K.J., Milne, S.A., Williams, A.R., Anderson, R.A. and Jabbour, H.N. (2004) Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. *J. Clin. Endocrinol. Metab.* 89, 986–993.
- [13] Corps, A.N., Cheek, T.R., Moreton, R.B., Berridge, M.J. and Brown, K.D. (1989) Single-cell analysis of the mitogen-induced calcium responses of normal and protein kinase C-depleted Swiss 3T3 cells. *Cell Regul.* 1, 75–86.
- [14] Sauane, M., Correa, L., Rogers, F., Krasnapolski, M., Barracough, R., Rudland, P.S. and de Asua, L.J. (2000) Prostaglandin F2(alpha) induces cyclin D1 expression and DNA synthesis via early signaling mechanisms in Swiss mouse 3T3 cells. *Biochem. Biophys. Res. Commun.* 270, 11–16.
- [15] Todaro, G.J. and Green, H. (1963) Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. *J. Cell Biol.* 17, 299–313.
- [16] Levy, C.S., Sauane, M., Rudland, P.S. and Jimenez de Asua, L. (1997) Leukaemia inhibitory factor induces mitogenesis in Swiss 3T3 cells and selective enhancement via a variety of signalling events. *Biochem. Biophys. Res. Commun.* 236, 814–818.
- [17] Raingeaud, J., Gupta, S., Rogers, J.S., Dickens, M., Han, J., Ulevitch, R.J. and Davis, R.J. (1995) Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. *J. Biol. Chem.* 270, 7420–7426.
- [18] Matsushime, H., Quelle, D.E., Shurtleff, S.A., Shibuya, M., Sherr, C.J. and Kato, J.Y. (1994) D-type cyclin-dependent kinase activity in mammalian cells. *Mol. Cell. Biol.* 14, 2066–2076.
- [19] Favata, M.F. et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J. Biol. Chem.* 273, 18623–18632.
- [20] Seufferlein, T., Withers, D.J. and Rozengurt, E. (1996) Reduced requirement of mitogen-activated protein kinase (MAPK) activity for entry into the S phase of the cell cycle in Swiss 3T3 fibroblasts stimulated by bombesin and insulin. *J. Biol. Chem.* 271, 21471–21477.
- [21] Philips, A., Roux, P., Coulon, V., Bellanger, J.M., Vie, A., Vignais, M.L. and Blanchard, J.M. (2000) Differential effect of Rac and Cdc42 on p38 kinase activity and cell cycle progression of nonadherent primary mouse fibroblasts. *J. Biol. Chem.* 275, 5911–5917.
- [22] Lavoie, J.N., L'Allemain, G., Brunet, A., Muller, R. and Pouyssegur, J. (1996) Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. *J. Biol. Chem.* 271, 20608–20616.
- [23] Weber, J.D., Raben, D.M., Phillips, P.J. and Baldassare, J.J. (1997) Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. *Biochem. J.* 326 (1), 61–68.